National Distributor and Logistic Services Provider
for pharmaceutical market, part of Interbrands Group
Orders
Europharm Distribution goes green in a fleet turnover worth 1 million euro

Europharm Distribution (EPH) announces the replacement of all its sales car fleet with hybrid vehicles by the end of January 2017. (Press release, January 25th, 2017)

 

Newly-acquired by Interbrands Marketing & Distribution SRL (IBR), the pharma distribution company announces the complete turnover of the fleet mainly destined for its sales force. Thus, a total of more than 80 passenger cars will be replaced by the end of January 2017 by Toyota Auris Terra Hybrid and Toyota Yaris Hybrid models, within a strategic partnership that IBR holds with Toyota in Romania. With more than 80 hybrid vehicles, this will be the largest hybrid fleet of a pharma distributor in Romania.

The total investment made by EPH amounts to 1 million euro and it is part of the company’s commitment to strengthen its position as one of the leading distributors and LSPs on the Romanian pharma market. As part of the investment program, EPH has also renewed its fleet of delivery vans in the past 12 months amounting to 1,500,000 euro.

 “As one of the most important players in the pharma distribution market, we feel responsible to provide high-quality services to our customers at all levels of our business. By replacing our entire sales force car fleet with hybrid vehicles, we are making sure to live up to this commitment. Also, it is part of our strategy for 2017 to continue to invest in the extension and improvement of the quality of sales force services and in the increase of geographical coverage in small urban and rural areas.”, stated Georgi Roussev, General Manager of EPH.

The green car fleet decision is the result of a first EPH synergy with IBR. In 2015 IBR announced the strengthening of its partnership with Toyota Romania through a new agreement concerning the replacement of all its car fleet with Toyota hybrid cars.

On November 1st, 2016, the acquisition of EPH by IBR group from GSK group became fully effective. As part of this transaction, EPH remains a standalone company within the IBR group and its role will not change due to this ownership change: EPH will continue its activity as one of the most important players in the pharmaceutical distribution market, providing customers and patients with the best healthcare products available.